Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245436 · ClinicalTrials.gov registry record · Phase 4
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
A Phase 4 study of Anxiety and Depressive Symptoms, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04245436: Recruiting Phase 4 study of Anxiety and Depressive Symptoms, sponsored by University of Cincinnati.
NCT04245436 is a Phase 4 study of Anxiety and Depressive Symptoms that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 60 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04245436, a Phase 4 study of Anxiety and Depressive Symptoms, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.
Conditions Studied
Interventions
- DRUG Duloxetine
- DRUG Escitalopram
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2025-08 |
| Phase | Phase 4 |
What NCT04245436 shows while recruiting
NCT04245436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Duloxetine is the first listed.
NCT04245436 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04245436 about?
NCT04245436 is a clinical study titled "Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)". Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.
What is the current status of trial NCT04245436?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2020-01-01. Estimated completion is 2025-08.
What conditions does trial NCT04245436 study?
This clinical trial studies the following conditions: Anxiety, Depressive Symptoms.
What interventions are being tested in trial NCT04245436?
The interventions under investigation include: Duloxetine (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT04245436?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04245436 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04245436's enrollment target sits among peer trials
60 230th of 364 higher than 127 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI